跳至主要内容
临床试验/NCT02565238
NCT02565238已完成不适用

Master Study of the Insertable Cardiac Monitor BioMonitor 2.

Biotronik SE & Co. KG0 个研究点目标入组 92 人开始时间: 2015年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
92
主要终点
Serious Adverse Device Effect (SADE)-free rate ≥ 90% related to BioMonitor 2

研究概览

简要总结

The objective of the study is to confirm safety and efficacy of the BioMonitor 2. The data is collected to support the regulatory approval of this product in countries outside the CE region.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients without history of atrial fibrillation and with an indication for BioMonitor 2 device or paients planned for loop recorded guided AF-therapy management, with either current known and documented paroxysmal atrial fibrillation or with current known and documented persistent atrial fibrillation indicated for an ablation or was ablated within the last four weeks.
  • Patient is able to understand the nature of the study and provides written informed consent.
  • Patient is able and willing to complete the planned follow-up visits at the investigational site.
  • Patient accepts the Home Monitoring® concept.
  • Age is ≥ 18 years.

排除标准

  • Patients implanted with ICD or pacemaker.
  • Patient who is pregnant and/or breast-feeding or who intends to become pregnant during the time of the study will be excluded.
  • Life expectancy of less than 6 months.
  • Participation in another interventional clinical investigation. Participation in a non-interventional study is permitted.

结局指标

主要结局

Serious Adverse Device Effect (SADE)-free rate ≥ 90% related to BioMonitor 2

时间窗: 3 month

次要结局

  • R-Wave amplitude ≥ 0.3 mV(1 week)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

BIO.MASTER.BioMonitor 2 Study | 临床试验